Morgan Stanley Sees Potential SNN Transaction As Good For Stryker

In a report published Thursday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $91.00 price target on

. In the report, Morgan Stanley noted, “The potential transaction may represent a small diversion from Stryker's recent strategy, but combining scale in orthopedics with inversion optionality creates a meaningful incentive for a deal. We see potential for up to 18% accretion and an 8% ROIC in 2017 through deal and inversion synergies.” Stryker closed on Wednesday at $82.64.